Journal
Clinical and Translational Radiation Oncology
Publication Date
1-1-2023
Volume
38
First Page
161
Last Page
168
Document Type
Open Access Publication
DOI
10.1016/j.ctro.2022.11.013
Rights and Permissions
Chuong MD, Clark MA, Henke LE, Kishan AU, Portelance L, Parikh PJ, Bassetti MF, Nagar H, Rosenberg SA, Mehta MP, Refaat T, Rineer JM, Smith A, Seung S, Zaki BI, Fuss M, Mak RH. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments. Clin Transl Radiat Oncol. 2022 Nov 22;38:161-168. doi: 10.1016/j.ctro.2022.11.013. © 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Chuong, Michael D; Henke, Lauren E; and et al., "Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments." Clinical and Translational Radiation Oncology. 38, 161 - 168. (2023).
https://digitalcommons.wustl.edu/oa_4/1464
